📊 FLGT Key Takeaways
Is Fulgent Genetics, Inc. (FLGT) a Good Investment?
Despite 13.8% revenue growth and a fortress balance sheet with minimal debt, Fulgent Genetics is severely unprofitable with -$34.6M operating losses on $71.1M revenue, indicating operating expenses are growing faster than sales and margins are deteriorating. While positive free cash flow and strong liquidity provide a financial cushion, the unsustainable -48.7% operating margin with no clear path to profitability presents substantial execution risk.
Fulgent Genetics shows respectable top-line growth and maintains a very strong balance sheet with high liquidity, no meaningful leverage, and substantial equity support. However, that growth is not translating into operating profitability or cash generation, with deeply negative operating margins and free cash flow indicating weak growth quality. The company appears financially durable, but the fundamentals do not yet support a clearly bullish view until losses and cash burn improve.
Why Buy Fulgent Genetics, Inc. Stock? FLGT Key Strengths
- Fortress balance sheet with $1.0B equity, minimal debt (0.00x leverage), and $23.4M cash providing multi-year runway
- Positive revenue growth at 13.8% YoY with healthy 30.2% gross margins indicating competitive pricing power
- Positive free cash flow of $1.9M despite losses, suggesting working capital discipline and non-cash charge management
- Revenue grew 13.8% year over year, indicating the business is still expanding
- Balance sheet is exceptionally strong with a 6.48x current ratio, minimal leverage, and over $1.1B in equity
- Gross margin of 40.6% suggests the core business retains decent underlying economics before overhead and operating costs
FLGT Stock Risks: Fulgent Genetics, Inc. Investment Risks
- Massive operating losses of -$34.6M (-48.7% margin) on $71.1M revenue indicates unsustainable cost structure and operating expenses growing faster than revenue
- Negative net income of -$24.8M with ROE and ROA both deeply negative, showing poor asset utilization and inability to convert revenue to profits
- Extremely thin FCF margin of 2.7% leaves minimal room for error; at current burn rate ($7.1M opex cash), company has approximately 3 years of runway despite strong balance sheet
- Operating margin of -28.2% shows the company is far from sustainable profitability
- Operating cash flow of -101.64M and free cash flow of -124.21M indicate significant cash burn
- Returns on equity and assets are negative, showing capital is not currently being deployed efficiently
Key Metrics to Watch
- Operating margin trajectory—must show improvement toward breakeven within 2-3 quarters to validate business model sustainability
- Operating expense ratio relative to revenue—needs to decline from current ~149% to <100% to restore profitability
- Cash burn rate and cash balance depletion timeline given widening operating losses outpacing revenue growth
- Operating margin improvement toward breakeven
- Operating cash flow and free cash flow trend
Fulgent Genetics, Inc. (FLGT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.7% FCF margin may limit capital allocation flexibility. Strong liquidity with a 5.31x current ratio provides a solid financial cushion.
FLGT Profit Margin, ROE & Profitability Analysis
FLGT vs Healthcare Sector: How Fulgent Genetics, Inc. Compares
How Fulgent Genetics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fulgent Genetics, Inc. Stock Overvalued? FLGT Valuation Analysis 2026
Based on fundamental analysis, Fulgent Genetics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fulgent Genetics, Inc. Balance Sheet: FLGT Debt, Cash & Liquidity
FLGT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fulgent Genetics, Inc.'s revenue has declined by 67% over the 5-year period, indicating business contraction. The most recent EPS of $-5.63 indicates the company is currently unprofitable.
FLGT Revenue Growth, EPS Growth & YoY Performance
FLGT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $71.1M | -$11.5M | $-0.37 |
| Q3 2025 | $71.7M | -$6.6M | $-0.21 |
| Q2 2025 | $71.0M | -$8.7M | $-0.29 |
| Q1 2025 | $64.5M | -$11.5M | $-0.37 |
| Q3 2024 | $71.7M | -$13.1M | $-0.44 |
| Q2 2024 | $67.9M | -$8.7M | $-0.29 |
| Q1 2024 | $64.5M | -$13.5M | $-0.45 |
| Q3 2023 | $84.7M | $1.7M | $0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fulgent Genetics, Inc. Dividends, Buybacks & Capital Allocation
FLGT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fulgent Genetics, Inc. (CIK: 0001674930)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FLGT
What is the AI rating for FLGT?
Fulgent Genetics, Inc. (FLGT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FLGT's key strengths?
Claude: Fortress balance sheet with $1.0B equity, minimal debt (0.00x leverage), and $23.4M cash providing multi-year runway. Positive revenue growth at 13.8% YoY with healthy 30.2% gross margins indicating competitive pricing power. ChatGPT: Revenue grew 13.8% year over year, indicating the business is still expanding. Balance sheet is exceptionally strong with a 6.48x current ratio, minimal leverage, and over $1.1B in equity.
What are the risks of investing in FLGT?
Claude: Massive operating losses of -$34.6M (-48.7% margin) on $71.1M revenue indicates unsustainable cost structure and operating expenses growing faster than revenue. Negative net income of -$24.8M with ROE and ROA both deeply negative, showing poor asset utilization and inability to convert revenue to profits. ChatGPT: Operating margin of -28.2% shows the company is far from sustainable profitability. Operating cash flow of -101.64M and free cash flow of -124.21M indicate significant cash burn.
What is FLGT's revenue and growth?
Fulgent Genetics, Inc. reported revenue of $71.1M.
Does FLGT pay dividends?
Fulgent Genetics, Inc. does not currently pay dividends.
Where can I find FLGT SEC filings?
Official SEC filings for Fulgent Genetics, Inc. (CIK: 0001674930) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FLGT's EPS?
Fulgent Genetics, Inc. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FLGT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Fulgent Genetics, Inc. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FLGT stock overvalued or undervalued?
Valuation metrics for FLGT: ROE of -2.4% (sector avg: 15%), net margin of -34.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FLGT stock in 2026?
Our dual AI analysis gives Fulgent Genetics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FLGT's free cash flow?
Fulgent Genetics, Inc.'s operating cash flow is $7.1M, with capital expenditures of $5.2M. FCF margin is 2.7%.
How does FLGT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34.9% (avg: 12%), ROE -2.4% (avg: 15%), current ratio 5.31 (avg: 2).